Roger Susi Sells 3,089 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 3,089 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $84.54, for a total value of $261,144.06. Following the completion of the sale, the chief executive officer owned 2,184,411 shares of the company’s stock, valued at approximately $184,670,105.94. The trade was a 0.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Trading Up 1.9%

NASDAQ IRMD opened at $86.89 on Friday. The stock has a market cap of $1.11 billion, a PE ratio of 47.48 and a beta of 0.90. iRadimed Corporation has a twelve month low of $50.88 and a twelve month high of $107.90. The stock has a fifty day simple moving average of $94.05 and a 200-day simple moving average of $94.73.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Research analysts predict that iRadimed Corporation will post 1.52 EPS for the current year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be issued a dividend of $0.20 per share. The ex-dividend date is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s dividend payout ratio is currently 43.72%.

Hedge Funds Weigh In On iRadimed

Several hedge funds have recently bought and sold shares of the company. CWM LLC lifted its stake in iRadimed by 19.5% during the 4th quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares in the last quarter. Johnson Investment Counsel Inc. lifted its stake in iRadimed by 0.7% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 25,842 shares of the medical equipment provider’s stock worth $1,839,000 after acquiring an additional 187 shares in the last quarter. Summit Global Investments lifted its stake in iRadimed by 2.7% during the 3rd quarter. Summit Global Investments now owns 7,139 shares of the medical equipment provider’s stock worth $508,000 after acquiring an additional 188 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in iRadimed by 4.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,824 shares of the medical equipment provider’s stock worth $567,000 after acquiring an additional 267 shares in the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on IRMD. Lake Street Capital reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Wednesday, February 11th. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 6th. Roth Mkm reiterated a “buy” rating and set a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Finally, Freedom Capital upgraded iRadimed to a “strong-buy” rating in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, iRadimed presently has a consensus rating of “Buy” and an average price target of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.